CSL appoints former ViiV and GSK veteran Deborah Waterhouse as new CEO

CSL announced that Deborah Waterhouse will become its chief executive. The appointment follows her departure from GSK, where she spent three decades.

Waterhouse most recently led ViiV Healthcare, GSK's HIV specialist, after a long career that included senior roles across the multinational. Her experience spans drug development, commercial strategy and global operations.

Analysts see the move as a signal that CSL aims to strengthen its leadership with seasoned biotech expertise, potentially accelerating its pipeline and expanding its presence in infectious disease markets.